GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VBI Vaccines Inc (OTCPK:VBIVQ) » Definitions » Effect of Exchange Rate Changes

VBIVQ (VBI Vaccines) Effect of Exchange Rate Changes : $0.14 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is VBI Vaccines Effect of Exchange Rate Changes?

VBI Vaccines's Effect of Exchange Rate Changes for the three months ended in Mar. 2024 was $-0.01 Mil.

VBI Vaccines's Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2024 was $0.14 Mil.


VBI Vaccines Effect of Exchange Rate Changes Historical Data

The historical data trend for VBI Vaccines's Effect of Exchange Rate Changes can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VBI Vaccines Effect of Exchange Rate Changes Chart

VBI Vaccines Annual Data
Trend Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effect of Exchange Rate Changes
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 0.27 0.33 -0.48 0.11

VBI Vaccines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effect of Exchange Rate Changes Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.29 0.26 0.19 -0.01

VBI Vaccines Effect of Exchange Rate Changes Calculation

Effect of Exchange Rate Changes represents the effect of exchange rate changes on cash balances held in foreign currencies.

Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VBI Vaccines Effect of Exchange Rate Changes Related Terms

Thank you for viewing the detailed overview of VBI Vaccines's Effect of Exchange Rate Changes provided by GuruFocus.com. Please click on the following links to see related term pages.


VBI Vaccines Business Description

Industry
Traded in Other Exchanges
N/A
Address
160 Second Street, Floor 3, Cambridge, MA, USA, 02142
VBI Vaccines Inc is a commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Executives
Steven Gillis director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Vaughn B Himes director C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Robert Dillman officer: Chief Commercial Officer C/O VBI VACCINES INC., 160 SECOND STREET, FLOOR 3, CAMBRIDGE MA 02142
Nell Beattie officer: Director, Corp Development/IR 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Linda Bain director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Damian Braga director 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Francisco Diaz-mitoma officer: Chief Medical Officer 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Christopher Mcnulty officer: CFO and Head of BD C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeff Baxter director, officer: President and CEO C/O VBI VACCINES INC.,, 222 THIRD STREET, STE 2241, CAMBRIDGE MA 02142
Joanne Cordeiro director 171 SWANTON STREET, UNIT 48, WINCHESTER MA 01890
Blaine H. Mckee director C/O HART, 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
Tomer Kariv director C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003